Performance Evaluation of Clostridium difficile GDH+Toxin A+Toxin B Combo Rapid Test Cassette (Feces, ICD-R635B) via Clinical Validation
MEDS Clinical Medicine · 2026 · 7 (3)
DOI: 10.23977/medsc.2026.070302 ↗Kurz gefasst
Fachartikel in der Zeitschrift MEDS Clinical Medicine, 2026.
Abstract (Originalsprache)
This clinical validation study comprehensively assesses the diagnostic performance of the Clostridium difficile GDH+Toxin A+Toxin B Combo Rapid Test Cassette (ICD-R635B, Hangzhou Alltest Biotech Co,.Ltd), an in vitro qualitative diagnostic device for simultaneous detection of Clostridium difficile glutamate dehydrogenase (GDH), Toxin A and Toxin B antigens in human fecal specimens. A commercial CERTEST Clostridium difficile GDH+Toxin A+B rapid test kit (CERTEST BIOTEC S.L.) was used as the reference assay for performance benchmarking. A total of 163 archived fecal specimens from patients with suspected Clostridium difficile infection (CDI) were enrolled, including 43 reference-positive and 120 reference-negative samples. The investigational assay yielded robust diagnostic performance: GDH relative sensitivity 97.7% (95% CI: 87.7%–99.9%), specificity 95.0% (95% CI: 89.4%–98.1%), accuracy 95.7% (95% CI: 91.4%–98.3%); Toxin A sensitivity 95.3% (95% CI: 84.2%–99.4%), specificity 97.5% (95% CI: 92.9%–99.5%), accuracy 96.9% (95% CI: 93.0%–99.0%); Toxin B sensitivity 95.3% (95% CI: 84.2%–99.4%), specificity 99.2% (95% CI: 95.4%–99.9%), accuracy 98.2% (95% CI: 94.7%–99.6%). All tests were performed within the validated operating temperature range (2-30°C). Test results were uniformly interpreted via the LF Reader Plus instrument for standardized, objective reading; no manual visual interpretation of test lines was performed per official product specifications, with final positive/negative/invalid results directly displayed on the instrument screen. All cassettes are single-use disposable devices. The investigational kit exhibited high concordance with the reference assay with no obvious cross-reactivity or abnormal invalid rates. This triple-biomarker rapid test provides reliable, fast point-of-care CDI detection for clinical laboratory and bedside screening.
Zitieren
APA
(2026). Performance Evaluation of Clostridium difficile GDH+Toxin A+Toxin B Combo Rapid Test Cassette (Feces, ICD-R635B) via Clinical Validation. MEDS Clinical Medicine, 7(3). https://doi.org/10.23977/medsc.2026.070302
Vancouver
Performance Evaluation of Clostridium difficile GDH+Toxin A+Toxin B Combo Rapid Test Cassette (Feces, ICD-R635B) via Clinical Validation. MEDS Clinical Medicine. 2026;7(3). doi:10.23977/medsc.2026.070302
BibTeX
@article{euvimed2026,
title = {Performance Evaluation of Clostridium difficile GDH+Toxin A+Toxin B Combo Rapid Test Cassette (Feces, ICD-R635B) via Clinical Validation},
journal = {MEDS Clinical Medicine},
year = {2026},
volume = {7},
number = {3},
doi = {10.23977/medsc.2026.070302}
}
EUVIMED